Search
Aluminum oxide
go.drugbank.com/drugs/DB11342ApprovedWithdrawnIt is amphoteric in nature, and is used in various chemical, industrial and commercial applications. It is considered an indirect additive used in food contact substances by the FDA.
Etesevimab
go.drugbank.com/drugs/DB15897Investigational[L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with [bamlanivimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for … [L40174] The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children.[L40179]
Danoprevir
go.drugbank.com/drugs/DB11779InvestigationalDanoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.
CTS-21166
go.drugbank.com/drugs/DB06073InvestigationalIn 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability … CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far.
Omega-6 fatty acids
go.drugbank.com/drugs/DB13168InvestigationalNutraceuticalCells involved in the inflammatory response are typically rich in the n-6 fatty acid arachidonic acid, as generally, eicosanoids derived from n-6 PUFA are pro-inflammatory. … Omega-6 fatty acids are polyunsaturated fatty acids with a final carbon-carbon double bond in the n-6 position, that is, the sixth bond, counting from the methyl end.
Synonyms: n-6 fatty acidsBI-K0376
go.drugbank.com/drugs/DB05858ExperimentalBI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.
FP0011
go.drugbank.com/drugs/DB05090ExperimentalFP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease). … It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties.
Drinabant
go.drugbank.com/drugs/DB05750InvestigationalIt is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease. … AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.
Anecortave acetate
go.drugbank.com/drugs/DB05288InvestigationalAnecortave acetate (Retaane) is an analog of cortisol acetate; among the modifications to the steroid are the removal of the 11ß hydroxyl OH group and an addition of a 21-acetate group. … As a result of these modifications, anecortave acetate lacks the typical antiinflammatory and immunosuppressive properties of glucocorticoids.Alcon Inc. is developing and marketing Retaane.